Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
Mitul Mehta, London, Camberwell, United Kingdom
CMHC, Substance Abuse Center, New Haven, Connecticut, United States
Laboratory of Translational Research NHLBI, Bethesda, Maryland, United States
Baylor College of Medicine - Ben Taub General Hospital, Houston, Texas, United States
University of Cincinnati, Cincinnati, Ohio, United States
CMHC, Substance Abuse Center, New Haven, Connecticut, United States
University of Texas Health Science Center-Houston, Houston, Texas, United States
Baylor College of Medicine, Houston, Texas, United States
University of Cincinnati, Cincinnati, Ohio, United States
Sheffield Teaching Hospitals NHS Trust, Sheffield, South Yorkshire, United Kingdom
Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States
University of Chicago, Chicago, Illinois, United States
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Decatur Memorial Hospital, Decatur, Illinois, United States
St Bartholomew's Hospital, London, Greater London, United Kingdom
The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
University College London Hospital, London, Greater London, United Kingdom
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
UCLA/Mattel's Children's Hospital, Los Angeles, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.